Clinical trials: Thromboembolism
Venous Thromboembolism
The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients
Trauma patients are at high risk of developing deep vein thrombosis (DVT) and pulmonary embolism (PE). The incidence of DVT varies greatly from 5-63% among studies depending on patient's individual risk factors, modality of…
- Trial name
- NCT00531843
- Testing
- fondaparinux sodium, sequential compression devices
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Mary Knudson, M.D.
Deep Venous Thrombosis
Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Trial
The purpose of this phase 2a, multi-center, randomized controlled study, is to explore the efficacy of early prophylaxis against catheter-associated deep venous thrombosis (CADVT) in critically ill children.
- Trial name
- CRETE (NCT03003390)
- Testing
- Enoxaparin
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- Yale University
Venous Thromboembolism, Deep Vein Thrombosis
OsciPulse Device for the Prevention of VTE
This is a Phase 2 safety and tolerability trial that will take place in two parts. Part one of the trial will determine the tolerability of the OsciPulse device on healthy subjects who wear the device for up to three hours.
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Thromboembolisms
- Trial name
- NCT04625673
- Testing
- OsciPulse
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
PE - Pulmonary Embolism, PE - Pulmonary Thromboembolism
FlowTriever All-Comer Registry for Patient Safety and Hemodynamics
To evaluate the safety and effectiveness of the FlowTriever System for use in the removal of emboli from the pulmonary arteries in the treatment of acute pulmonary embolism (PE).
- Trial name
- FLASH (NCT03761173)
- Testing
- FlowTriever System, Anticoagulation Agents
- Where
- 81 sites in United States, Austria and 7 more
- Volunteers
- 1,200 people
- Sponsor
- Inari Medical
Venous Thromboembolism
A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
The objective of this study is to assess the efficacy and safety of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total knee arthroplasty.
- Trial name
- NCT01181102
- Testing
- edoxaban, enoxaparin sodium
- Where
- 3 sites in Japan, Taiwan
- Volunteers
- 716 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
COVID-19, Venous Thromboses
Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19
This study is being conducted to assess the effectiveness of intermediate versus prophylactic doses of anticoagulation (blood thinners) in patients critically ill with COVID-19 in the intensive care units (ICUs) throughout the…
- Conditions
- COVID-19, Venous Thromboses, Arterial Thrombosis
- Trial name
- IMPROVE (NCT04367831)
- Testing
- Enoxaparin Prophylactic Dose, Heparin Infusion, Heparin SC
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Columbia University
Venous Thromboembolism
Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients
The purpose of this study is to compare the efficacy and safety of dalteparin vs unfractionated heparin for the prevention of VTE (Venous Thromboembolism) in hospitalized acutely ill medical patients.
- Trial name
- NCT00445328
- Testing
- Dalteparin (Fragmin), Unfractionated heparin
- Where
- 7 sites in India
- Volunteers
- 84 people
- Sponsor
- Pfizer
Pulmonary Embolism, Chronic Obstructive Pulmonary Disease
Pulmonary Embolism as a Cause of COPD Exacerbations
The primary objective is to demonstrate the clinical benefits of an active strategy for the diagnosis and treatment of PE compared to usual care in patients with unexplained exacerbations of COPD who require hospital admission.
- Trial name
- SLICE (NCT02238639)
- Testing
- Diagnostic and therapeutic strategy: Highly sensitive D-dimer testing and, if positive, multidetector computed tomographic pulmonary angiography (MDCT).
- Where
- 19 sites in Spain
- Volunteers
- 746 people
- Sponsor
- Ministry of Health, Spain
Arthroplasty, Replacement, Thromboembolism
Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery
An observational cohort study on safety and efficacy to generate additional data on the benefit/risk profile of the 150 mg dose of Pradaxa in patients with renal impairment
- Trial name
- NCT00847301
- Where
- 53 sites in Austria, France and 5 more
- Volunteers
- 472 people
- Sponsor
- Boehringer Ingelheim
Arthroplasty, Replacement, Knee, Thromboembolism
RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery
A phase III, randomised, parallel-group, double-blind, active controlled study to investigate the ef ficacy and safety of two different dose regimens of orally administered dabigatran etexilate capsule s [150 or 220 mg once daily…
- Trial name
- NCT00168805
- Testing
- enoxaparin, dabigatran etexilate
- Where
- 105 sites in Australia, Austria and 13 more
- Volunteers
- 2,101 people
- Sponsor
- Boehringer Ingelheim
Thromboembolism of Vein VTE in Colorectal Cancer, Thromboembolism of Vein in Pancreatic Cancer
Cancer Associated Thrombosis and Isoquercetin (CATIQ)
This research study is evaluating a drug called isoquercetin to prevent venous thrombosis (blood clots), in participants who have pancreas, non small cell lung cancer or colorectal cancer.
- Conditions
- Thromboembolism of Vein VTE in Colorectal Cancer, Thromboembolism of Vein in Pancreatic Cancer, Thromboembolism of Vein in Non-small Cell Lung Cancer
- Trial name
- CATIQ (NCT02195232)
- Testing
- Isoquercetin
- Where
- 11 sites in United States
- Volunteers
- 64 people
- Sponsor
- Jeffrey Zwicker, MD
Venous Thromboembolism
A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
The main research question of this study is to obtain further safety and effectiveness data on Pradaxa Pellets in children aged 3 months to less than 12 years in routine clinical practice setting.
- Trial name
- NCT05966740
- Where
- 10 sites in United States
- Volunteers
- 5 people
- Sponsor
- Boehringer Ingelheim
Patients With Atrial Fibrillation at Risk for Thrombus Formation, Thromboembolism, Stroke
Registry on WATCHMAN Outcomes in Real-Life Utilization
The WATCHMAN LAA Closure Technology is designed to prevent embolization of thrombi that may form in the LAA, thereby preventing the occurrence of ischemic stroke and systemic thromboembolism.
- Trial name
- EWOLUTION (NCT01972282)
- Testing
- WATCHMAN Left Atrial Appendage Closure
- Where
- 47 sites in Belgium, France and 11 more
- Volunteers
- 1,025 people
- Sponsor
- Boston Scientific Corporation